Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1999 2
2000 1
2004 1
2005 1
2008 1
2009 1
2010 3
2011 4
2012 6
2013 5
2014 9
2015 2
2016 3
2017 4
2018 4
2019 6
2020 6
2021 9
2022 11
2023 6
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. de Masson A, et al. Among authors: moins teisserenc h. Lancet. 2023 Jun 10;401(10392):1941-1950. doi: 10.1016/S0140-6736(23)00329-X. Epub 2023 Apr 24. Lancet. 2023. PMID: 37105210
TAP deficiency syndrome.
Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. Gadola SD, et al. Among authors: moins teisserenc ht. Clin Exp Immunol. 2000 Aug;121(2):173-8. doi: 10.1046/j.1365-2249.2000.01264.x. Clin Exp Immunol. 2000. PMID: 10931128 Free PMC article. Review. No abstract available.
Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome.
Laurent C, Lefèvre G, Kahn JE, Staumont-Salle D, Felten R, Puget M, Moulinet T, Machelart I, Launay D, Charvet E, Bouaziz JD, Jachiet M, Espitia A, Mahr A, Le Clech C, Malphettes M, Morice C, Mourah S, Moins-Teisserenc H, Lifermann F, Soulier-Guérin K, Villate A, Baillou C, Grados A, Robbins A, Abisror N, Bagot M, Boutboul D, Panel K, Vignon-Pennamen MD, Rivet J, Battistella M, Groh M, de Masson A; CEREO network. Laurent C, et al. Among authors: moins teisserenc h. Br J Dermatol. 2022 Dec;187(6):1011-1013. doi: 10.1111/bjd.21782. Epub 2022 Aug 12. Br J Dermatol. 2022. PMID: 35862277 Free PMC article.
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
Bozonnat A, Beylot-Barry M, Dereure O, D'Incan M, Quereux G, Guenova E, Perier-Muzet M, Dalle S, Grange F, Viguier MA, Ram-Wolff C, Feldmeyer L, Beltraminelli H, Bonnet N, Amatore F, Maubec E, Franck N, Machet L, Chasset F, Brunet-Possenti F, Bouaziz JD, Battistella M, Donzel M, Pham-Ledard A, Bejar C, Moins-Teisserenc H, Mourah S, Saiag P, Hainaut E, Michel C, Bens G, Adamski H, Aubin F, Boulinguez S, Joly P, Tedbirt B, Templier I, Troin L, Montaudié H, Ingen-Housz-Oro S, Faiz S, Mortier L, Dobos G, Bagot M, Resche-Rigon M, Montlahuc C, Serret-Larmande A, de Masson A; Cutaneous Lymphomas French Study Group. Bozonnat A, et al. Among authors: moins teisserenc h. EClinicalMedicine. 2024 Jun 21;73:102679. doi: 10.1016/j.eclinm.2024.102679. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 39007062 Free PMC article.
Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas.
Giustiniani J, Ta VA, Belkhelouat S, Battistella M, Ouahbi D, Ram-Wolff C, Louveau B, Mourah S, Bagot M, Moins-Teisserenc H, Ortonne N, Bensussan A, De Masson A. Giustiniani J, et al. Among authors: moins teisserenc h. J Invest Dermatol. 2024 Oct;144(10):2329-2332. doi: 10.1016/j.jid.2024.03.019. Epub 2024 Mar 28. J Invest Dermatol. 2024. PMID: 38555062 Free article. No abstract available.
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M. Leupin N, et al. Among authors: moins teisserenc h. Cancer. 2022 Mar 1;128(5):1004-1014. doi: 10.1002/cncr.34005. Epub 2021 Nov 2. Cancer. 2022. PMID: 34726773 Free article. Clinical Trial.
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M.
Fandrei D, Huynh T, Sébert M, Aguinaga L, Bisio V, Kim R, Clappier E, Espéli M, Balabanian K, Moins-Teisserenc H, Toubert A, Dulphy N, Fenaux P, Adès L, Zhao LP. Fandrei D, et al. Among authors: moins teisserenc h. Blood Cancer J. 2023 Dec 21;13(1):193. doi: 10.1038/s41408-023-00965-w. Blood Cancer J. 2023. PMID: 38123548 Free PMC article. No abstract available.
CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas.
Ta VA, Battistella M, Zhao LP, Dobos G, Ram-Wolff C, Madelaine I, Bories JC, Tournilhac O, Rouanet J, Veyrat-Masson R, Bouaziz JD, Marie-Cardine A, Bagot M, Bensussan A, Moins-Teisserenc H, De Masson A. Ta VA, et al. Among authors: moins teisserenc h. J Invest Dermatol. 2023 Jul;143(7):1329-1332.e3. doi: 10.1016/j.jid.2023.01.009. Epub 2023 Jan 28. J Invest Dermatol. 2023. PMID: 36716922 Free article. No abstract available.
81 results